TABLE 4.

Pharmacodynamics of ciprofloxacin in neutropenic rats infected with Pseudomonas aeruginosa ATCC 27853 following single i.v. administrations as bolus and infusions^a

Treatment	Mean ± SD P. aeruginosa burden (log10 CFU/g thigh [reductionb])
	i.v. bolus	30-min i.v. infusion	1-h i.v. infusion
Infection control (2 h PI)	6.13 ± 0.22	NA	NA
Vehicle control (26 h PI)	8.47 ± 0.13	NA	NA
Ciprofloxacin, 26 h PIc (mg/kg)
10	6.5 ± 0.11d	6.6 ± 0.12 d,e	7.66 ± 0.2f,g
30	5.3 ± 0.28h (0.83)	5.2 ± 0.08h,i (0.93)	4.2 ± 0.2h,j (1.9)
100	2.2 ± 0.18h (3.9)	1.86k (4.3)	BLOQ

^aNA, not applicable; PI, post infection; BLOQ, below the limit of quantitation.

^bValues in parentheses indicate the mean reduction in bacterial burden compared to that of the 2-h PI control at 24 h posttreatment.

^c26 h PI is equivalent to 24 h posttreatment.

^dNot significantly different compared to 2-h PI control (P < 0.05).

^eNot significantly different compared to 10 mg/kg i.v. bolus (P > 0.05).

^fSignificantly different compared to 10 mg/kg i.v. bolus (P < 0.05).

^gSignificantly different from vehicle control (P < 0.05).

^hSignificantly different compared to 2-h PI control (P < 0.05).

ⁱNot significantly different compared to 30 mg/kg i.v. bolus (P > 0.05).

^jSignificantly different compared to 30 mg/kg i.v. bolus (P < 0.05).

^kMean (n = 2).